Somewhat Positive Press Coverage Somewhat Unlikely to Impact NeoGenomics (NEO) Stock Price

Press coverage about NeoGenomics (NASDAQ:NEO) has been trending somewhat positive this week, Accern reports. The research firm identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. NeoGenomics earned a news sentiment score of 0.18 on Accern’s scale. Accern also assigned news coverage about the medical research company an impact score of 43.3722356290789 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Shares of NeoGenomics (NEO) opened at $9.13 on Friday. The stock has a market cap of $734.14, a PE ratio of 182.60, a PEG ratio of 8.70 and a beta of 0.85. The company has a quick ratio of 1.99, a current ratio of 2.14 and a debt-to-equity ratio of 0.57. NeoGenomics has a fifty-two week low of $7.12 and a fifty-two week high of $11.63.

NeoGenomics (NASDAQ:NEO) last announced its earnings results on Wednesday, October 25th. The medical research company reported $0.01 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.01. NeoGenomics had a negative net margin of 4.78% and a positive return on equity of 3.97%. The company had revenue of $63.05 million for the quarter, compared to analysts’ expectations of $63.11 million. During the same period last year, the firm earned $0.04 earnings per share. The business’s revenue for the quarter was up 3.8% on a year-over-year basis. analysts predict that NeoGenomics will post 0.04 earnings per share for the current year.

NEO has been the subject of several recent research reports. Janney Montgomery Scott reiterated a “buy” rating on shares of NeoGenomics in a research report on Thursday, October 26th. Zacks Investment Research raised shares of NeoGenomics from a “sell” rating to a “hold” rating in a research note on Thursday, October 26th. BidaskClub lowered shares of NeoGenomics from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, October 18th. BTIG Research lowered shares of NeoGenomics from a “buy” rating to a “neutral” rating in a research note on Monday, September 11th. Finally, Gabelli started coverage on shares of NeoGenomics in a research note on Thursday, August 24th. They issued a “buy” rating and a $9.00 target price for the company. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company. NeoGenomics presently has an average rating of “Buy” and an average price target of $10.33.

TRADEMARK VIOLATION WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact NeoGenomics (NEO) Stock Price” was originally reported by Community Financial News and is the property of of Community Financial News. If you are reading this story on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at

About NeoGenomics

NeoGenomics, Inc is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee.

Insider Buying and Selling by Quarter for NeoGenomics (NASDAQ:NEO)

What are top analysts saying about NeoGenomics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for NeoGenomics Inc. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit